Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human (FIH), Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer

NCT07321106 is registered in ClinicalTrials.gov with Cartography Biosciences as lead sponsor.

NCT NCT07321106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07321106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human (FIH), Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer
Lead sponsor
Cartography Biosciences
Phase
Phase 1
Overall status
Recruiting
Start date
January 15, 2026
Completion date
October 31, 2029
Enrollment
80 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer, colon cancer, colorectal (colon or rectal) cancer, colorectal cancer, colorectal cancer (crc), crc, metastatic colon cancer